Asthma therapeutics--SMi conference: 31 April-1 May 2003, London, UK.
Lunec
Anna
A
Thomson Current Drugs, London, UK. anna.lunec@current-drugs.com
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D006801:Humans; D039041:Integrin alpha4beta1 / Q000037:antagonists & inhibitors; D048031:JNK Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors; D009841:Oligonucleotides / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors
D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D039041:Integrin alpha4beta1; D009841:Oligonucleotides; D011743:Pyrimidines; D019707:Receptors, Chemokine; D048031:JNK Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4; D020929:Mitogen-Activated Protein Kinase Kinases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4